GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2007

Merck & Co. Resolves Dispute between Protiva and Its Subsidiary

  • Merck & Co  killed two birds with one broad agreement with Protiva. The company will drop charges against Merck subsidiary, Sirna Therapeutics, allowing the transfer of important technology from Sirna to Merck according to the $1.1 billion acquisition deal. Additionally, Protiva granted Merck nonexclusive rights to its SNALP (stable nucleic acid-lipid particles) technology for R&D of RNAi therapeutics.

    Protiva filed a lawsuit against Sirna alleging that the company had wrongfully used and disclosed its IP. The firm obtained an injunction from the Superior Court of California prohibiting Sirna from using, disclosing, transferring, licensing, selling, or otherwise encumbering Protiva’s trade secrets and know-how, except as permitted in the target areas defined in their original strategic alliance agreement.

    In relation to the licensing deal, Protiva will receive a one-time payment with the potential for development milestone fees and royalties.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?